Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Monday lulv 8

a w -ow p. -- -.. -. -. -.. - -7

MoPeB31o4 Laboratory and field evaluation of the
performance of simple and rapide HIV tests in
Mozambique
S C P Stakteas, A Tanuri2, M Rayfield3, A Vergara',
I Samo-Gudo', A Barreto1 (Mozambique; 2Brazil;
3United States)
MoPeB31o5 Less expensive CD4+ T cell monitoring using
panleucogating
M Wila1, G Janossy2, D Glencross3, D Barnett2,
J Mermin', R G Downing' (Uganda;
2United Kingdom; 3South Africa)
MoPeB31o6 Evaluating the Cavidi reverse transcriptase assay
to monitor response to anti-retroviral therapy
R Downin', G AnyaeganiP, J Mermin, A Malmsten2,
S Gronowitz2, G Corrigan2 (1Uganda; 2Sweden)
MoPeB31o7 HIV p24 antigen is recandidated as a sentinel
marker of viral replication by an innovative and
inexpensive assay
0 E Varnier I Martini, F Bertolotti, M Giacomini,
j L McDermott (Italy)
MoPeB31o8 Evaluation of the concomitant use of two EIA
tests for HIV blood bank screening
E C Sabino N A Salles, A M Barreto, M M Otani,
D F Chamone (Brazil)
MoPeB31o9 Development of a GAG based NASBA-molecular
beacon assay to distinguish between subtype C
and C' HIV-1 infection in Ethiopia: potential for
application in H IV-1 intervention strategies
WAyele1, M de Boaar2, A Abebe, G Pollakis2,
Y Mengistu W Dorigo-Zetsma, D Wolday',
B van Gemen2, J Goudsmit2
(lEthiopia; 2The Netherlands)
MoPeB311o Evaluation of the performance of non-laboratory
staff in the use of simple rapid HIV antibody
assays at New Start voluntary counseling and
testing (VCT) centers
ZZiyambi P Osewe, N Taruberekera (Zimbabwe)
MoPeB3111 Validation of the Serodia~ HIV kit for HIV
screening on dried blood spots from adolescents
in northern Tanzania
D Everett, J Changalucha, A Anemona, D A Ross,
D Mabey (Tanzania)
MoPeB3112 Role of total lymphocyte count for monitoring
HAART in a resource-constrained setting
M Badri, R Wood (South Africa)
MoPeB3113 Feasibility and accuracy of rapid on-site H IV tests
in antenatal clinics in urban Zimbabwe
N Nyoni1, P Mateta, M T Bassett', Y Maldonado2,
J Wells1, D Katzeinstein2, A K Shetty2
(Zimbabwe; 2United States)
MoPeB3114 An evaluation of anti-HIV test results in 59
institutions in Brazil, 2001
C Ferreira 0 C Ferreira Jr., JA P Ferreira,
M C Dantas, I Pedrosa, CM Capitani (Brazil)
MoPeB3115 Evaluation of a National AIDS Program
centralized net for viral load testing in the north
and center of Argentina
S Benetti, M Campodonico, F Fay, A Asueta, 0 Fay
(Argentina)
MoPeB3116 The acceptability and quality of self-administered
vaginal swabs among adolescents in rural
Tanzania
A Anemona M Plummer, I Chilongani, I Womoyi,
D Everett, I Changalucha, D Ross, R Hayes,
D Mabey (Tanzania)
MoPeB3117 HIV/AIDS diagnostic support, WHO's minimum
requirements for laboratory monitoring of ARV

therapy in countries with limited resources
G Vercauteren, H Ostensen, C Burgess,
I C Emmanuel (Switzerland)

MoPeB3118 An international program (QASI) supported the
implementation of an external quality assessment
program for CD4+ T-Cell measurement in Brazil to
assist the fight against AIDS
M Bergeron', G Houle, I Bradley2, Fahey3,
E G Kallas4, F P Barcellos, M CS Dantas,
P R Teixeira4, FMandy (Canada; 2Australia;
3United States; 4Brazil)
MoPeB3119 Comparison of two alternative CD4 T-cell
enumerating methods suitable for laboratories
with low volume immunophenotyping in
resource-poor settings
A Sherring, M Bergeron, F Mandy (Canada)
MoPeB312o Diagnostic value of the fourth-generation Human
Immunodeficiency Virus assay (antigen and
antibodies combined detection) in the routine
screening
J Lopez-Barba, I Solino-Ocana, S Garcia-Valdivia,
M Rodriguez-/glesias (Spain)
MoPeB3121 Plasma levels of soluble CD27: a simple marker
to monitor immune activation during potent
antiretroviral therapy in HIV-i-infected subjects
A De Milito1, S Aleman', R Marenzi,
A Sbnnerborg', D Fuchs2, M Zazzi3, F Chiodi
(Sweden; 2Austria; 3/taly)
MoPeB3122 Utility of a commercial stabilized whole blood
preparation, in an International Quality Assessment
program for CD4 T-cell Enumeration (QASI)
M Bergeron', N Soucy, T Ding1, G Houle,
J Fahey2, D Flagler2, R Mills2, F Mandy'
('Canada; 2United States)
MoPeB3123 Cost-effectiveness of anti-HIV-1 antibody testing
using modified gelatin particle agglutination:
a large field study
S louisirirotchanakul, C Kanoksinsombat,
A Thongput, A Puthavathana, C Wasi (Thailand)
MoPeB3124 Genotypic resistance analysis following singledose administration of nevirapine to HIV-infected
women and their infants receiving short-course
zidovudine
W Leelawiwat, P Wirachsilp', R Sutthent,
T Chaowanachan', M Culnane, A Teeraratkul,
R J Simonds2, N L Young'
('Thailand; 2United States)
MoPeB3125 Discrepant results in the interpretation of HIV-1
drug-resistance genotypic data among widely
used algorithms
G H Kiak', A E Rubio', C Zala', P Cahn',
P R Harrigan2, R GallP2, JS Montaner2, H Salomon'
('Argentina; 2Canada)
MoPeB3126 Construction of a new minimized retroviral vector
(pCHUS) derived from pNL4-3 plasmid
M L Abad, T Verdura, A Vela, M J Iglesias,
D Gutierrez, M Veiga, A Aguilera, B J Regueiro
(Spain)
MoPeB3127 Detection of HIV-1 antiretroviral resistance
mutations using a DNA Chip technology
] N Telles, R Gonzalez, C Hebrard, N Tran,
R Segura, B Masquelier, H Fleury, A Troesch,
G Vernet (France)
MoPeB3128 Generation of mutations in pol gene for
improving HIV-1 phenotypic resistance method
M /glesias, T Verdura, M L Abad, A Vela,
D Gutierrez, M Veiga, A Aguilera, B I Regueiro
(Spain)
MoPeB3129 Should resistance testing be done in
antiretroviral-na've patients? A cost-effectiveness

analysis
PE Sax, R Islam, E Losina, M C Weinstein,
C J Cohen, KA Freedberg (United States)
XIV International AIDS Conference BARCELONA - JULY 7-12

Monday

35